PIONEER is Evaxion’s immuno-oncology platform focused on developing personalized cancer immunotherapies. It uses sophisticated algorithms to identify and select those neo-epitopes (tumor-specific mutations) that are most likely to generate a profound anti-cancer immune response. The newly identified neoepitopes are then applied in a therapeutic immunization strategy which delivers personalized, synthetic neoepitopes to patients.

Home page of this offering   provided by Evaxion Biotech